Motilal Oswal Financial Services has recommended a buy on Biocon, targeting a price of Rs 430. The company, a leader in the pharmaceuticals sector, recently reported a quarterly income of Rs 3622.90 crore and a net profit of Rs 27.10 crore. Anticipated growth in biologics sales and operational improvements are key rationales behind this recommendation.
